 IRVINE, Calif.--BUSINESS WIRE--Axonics, Inc. Nasdaq: AXNX, a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed public offering of 150,000,000 in shares of its common stock. Axonics expects to grant the underwriters a 30-day option to purchase up to 22,500,000 in additional shares of its common stock at the public offering price, less the underwriting d 